Millions of people living with diabetes face the looming threat of vision loss from diabetic retinopathy, a condition where high blood sugar damages blood vessels in the retina. But a new discovery from researchers at University College London (UCL) offers a potential turning point in how we approach this debilitating disease. Scientists have identified a protein, LRG1, that appears to initiate the earliest stages of retinal damage, opening the door to therapies that could prevent blindness before it begins.
Diabetic retinopathy is a leading cause of vision loss among working-age adults, affecting individuals with both type 1 and type 2 diabetes. Current treatments, while helpful, often come too late, after significant and irreversible damage has already occurred. This new research, published in Science Translational Medicine, suggests a way to intervene much earlier in the disease process, potentially preserving sight for a far greater number of people. The study, supported by Diabetes UK, Moorfields Eye Charity, and Wellcome, focused on experiments using mouse models and has generated considerable excitement within the medical community.
LRG1: The Early Trigger of Retinal Damage
The research team found that LRG1 causes the cells surrounding the retina’s smallest blood vessels to constrict excessively, effectively “squeezing” them. This constriction reduces oxygen delivery to the retina, initiating a cascade of events that ultimately leads to vision impairment. Crucially, when scientists blocked the activity of LRG1 in diabetic mouse models, the early retinal damage did not occur, and normal eye function was maintained. This suggests that targeting LRG1 could be a highly effective strategy for preventing the progression of diabetic retinopathy.
“Our discovery shows that diabetic eye disease starts earlier than we thought, and LRG1 is a key culprit in this early damage,” explained Dr. Giulia De Rossi, lead author of the study from the UCL Institute of Ophthalmology. “Targeting this protein could give us a way to protect vision before serious damage occurs and prevent, rather than treat, blindness in millions of people living with diabetes.”
Why Current Treatments Fall Short
Existing treatments for diabetic retinopathy primarily focus on a different protein called vascular endothelial growth factor (VEGF). While these therapies can be effective, they only work for approximately half of patients and typically don’t reverse existing damage. According to research, nearly a third of adults with diabetes show signs of retinopathy, making it one of the most feared complications of the disease. The UCL team’s findings suggest that LRG1 initiates damage earlier than VEGF, making it a potentially more promising therapeutic target.
Dr. Faye Riley, research communications lead at Diabetes UK, highlighted the significance of the discovery, stating, “By identifying the root cause of early damage, and offering a new path for treatment, this research holds immense promise for protecting the sight of the growing number of people with diabetes worldwide.”
A New Therapy on the Horizon
The UCL research team has already developed a drug specifically designed to target LRG1. This therapeutic has undergone preliminary testing and is currently undergoing further preclinical research. Scientists are optimistic that it could move into human clinical trials in the near future. Researchers believe this therapy could not only prevent the development of diabetic retinopathy but also benefit individuals with more advanced disease, as LRG1 continues to contribute to damage even in later stages.
The breakthrough builds on years of research by scientists at the UCL Institute of Ophthalmology investigating the role of LRG1 in eye disease. Professors John Greenwood and Stephen Moss, co-authors of the study, were among the first to identify LRG1’s role in ocular conditions. In 2019, they founded Senya Therapeutics, a UCL spinout company dedicated to developing drugs that target LRG1.
Professor Greenwood, a world expert in LRG1 biology, emphasized the clinical potential of the findings: “This study delivers vital insight into the disease and shows that therapeutic targeting of LRG1 has real clinical potential. The discovery that LRG1 is an early initiating factor driving diabetic retinopathy is enormously exciting.” Professor Emeritus Moss added, “The solid news to accompany these findings is that we have already developed an LRG1 therapeutic ready for clinical trials. This could provide an effective new option for patients, especially those in the early stages of disease who don’t respond to existing treatments.”
Dr. Ailish Murray, director of grants and research at Moorfields Eye Charity, underscored the importance of early intervention, noting that the early stages of diabetic retinopathy are often difficult to detect, leading to irreversible damage by the time symptoms appear. Morag Foreman, head of discovery researchers at Wellcome, called the discovery “an exciting breakthrough, lighting a potential path towards treatment for diabetic eye disease.”
The next steps involve rigorous clinical trials to assess the safety and efficacy of the LRG1-targeting therapy in humans. While challenges remain, this research offers a beacon of hope for millions at risk of vision loss from diabetic retinopathy.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this promising new research? Share your comments below, and support spread awareness by sharing this article with your network.
